NCT01879332View on ClinicalTrials.gov

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Epilepsy
Interventions
DRUG

Placebo

Matching placebo tablets for oral administration

DRUG

BIA 2-093 3000 mg once daily

Eslicarbazepine acetate 600 mg tablets for oral administration

DRUG

BIA 2-093 3600 mg once daily

Eslicarbazepine acetate 600 mg tablets for oral administration

Trial Locations (1)

33025

Comprehensive Phase OneTM, Miramar

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT01879332 - A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter